60 Degrees Pharma enrolls first patient in tafenoquine babesiosis study at Tufts Medical Center

60 DEGREES PHARMACEUTICALS, INC.

IRB approval received for open-label expanded access study of tafenoquine in immunocompromised patients with persistent babesiosis.
Goal is to confirm 80% cure rate (30-100% CI) from Yale April 2024 case series published in Clinical Infectious Diseases.
Three-part program: acute hospitalized (enrolling), expanded access (announced), and chronic babesiosis (planned, gated by NC State study).
Company plans to file NDA for supplemental babesiosis indication by Q2 2026.
U.S. accessible market estimate: 38,000 acute immunosuppressed patients and at least 375,000 chronic babesiosis patients through 2035.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.